Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRA Biomerica	$3.69 +21.7%	$3.29	$2.08 ▼ $10.16	$9.65M	0.26	652,589 shs	38.63 million shs
CLRB Cellectar Biosciences	$4.40 -0.6%	$6.82	$4.31 ▼ $68.70	$7.96M	0.42	224,024 shs	541,580 shs
TAOX Synaptogenix	$8.94 -6.5%	$0.00	$1.84 ▼ $11.98	$12.43M	1.87	436,906 shs	320,366 shs
TNFA TNF Pharmaceuticals	$0.10 -3.8%	$0.12	$0.08 ▼ $2.16	$1.43M	1.82	14.86 million shs	18.31 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRA Biomerica	+3.01%	-2.22%	+1.65%	-16.08%	+22.97%
CLRB Cellectar Biosciences	-4.12%	-7.53%	-11.24%	-41.93%	-92.71%
TAOX Synaptogenix	+14.63%	+53.70%	+955,999,900.00%	+955,999,900.00%	+955,999,900.00%
TNFA TNF Pharmaceuticals	-4.55%	+0.48%	+2.84%	-46.78%	+10,499,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMRA Biomerica	1.3289 of 5 stars	0.0	5.0	0.0	0.0	3.8	0.8	0.0
CLRB Cellectar Biosciences	2.6976 of 5 stars	3.2	2.0	0.0	0.0	3.1	1.7	1.3
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TNFA TNF Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRA Biomerica	0.00	N/A	N/A	N/A
CLRB Cellectar Biosciences	2.50	Moderate Buy	$375.00	8,432.42% Upside
TAOX Synaptogenix	0.00	N/A	N/A	N/A
TNFA TNF Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TNFA, CLRB, BMRA, and TAOX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/14/2025	CLRB Cellectar Biosciences	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/14/2025	CLRB Cellectar Biosciences	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRA Biomerica	$5.41M	1.74	N/A	N/A	$3.13 per share	1.18
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	$8.98 per share	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	$4.33 per share	N/A
TNFA TNF Pharmaceuticals	N/A	N/A	N/A	N/A	$2.87 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRA Biomerica	-$5.98M	-$2.32	N/A	∞	N/A	-85.42%	-85.90%	-61.06%	8/27/2025 (Estimated)
CLRB Cellectar Biosciences	-$44.58M	-$21.92	N/A	N/A	N/A	N/A	-619.70%	-158.04%	8/14/2025 (Estimated)
TAOX Synaptogenix	-$12.77M	-$10.08	N/A	∞	N/A	N/A	-115.28%	-58.31%	N/A
TNFA TNF Pharmaceuticals	-$23.36M	-$6.67	N/A	∞	N/A	N/A	-97.38%	-37.37%	8/18/2025 (Estimated)

Latest TNFA, CLRB, BMRA, and TAOX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	CLRB Cellectar Biosciences	-$3.60	-$3.39	+$0.21	-$3.39	N/A	N/A
5/15/2025	Q1 2025	TNFA TNF Pharmaceuticals	N/A	-$0.36	N/A	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRA Biomerica	N/A	N/A	N/A	N/A	N/A
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A
TNFA TNF Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRA Biomerica	N/A	3.76	2.76
CLRB Cellectar Biosciences	N/A	2.47	2.47
TAOX Synaptogenix	N/A	72.59	72.59
TNFA TNF Pharmaceuticals	N/A	1.37	1.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRA Biomerica	22.28%
CLRB Cellectar Biosciences	16.41%
TAOX Synaptogenix	10.34%
TNFA TNF Pharmaceuticals	9.64%

Insider Ownership

Company	Insider Ownership
BMRA Biomerica	15.00%
CLRB Cellectar Biosciences	5.04%
TAOX Synaptogenix	2.73%
TNFA TNF Pharmaceuticals	0.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRA Biomerica	60	2.55 million	2.16 million	Optionable
CLRB Cellectar Biosciences	10	1.81 million	1.72 million	Optionable
TAOX Synaptogenix	4	1.39 million	1.35 million	N/A
TNFA TNF Pharmaceuticals	6	14.18 million	14.12 million	N/A

TNFA, CLRB, BMRA, and TAOX Headlines

Recent News About These Companies

TNF Pharmaceuticals Inc Ordinary Shares TNFA - Morningstar

July 11, 2025 | morningstar.comM

TNF Pharmaceuticals, Inc. (TNFA) - Yahoo Finance

June 27, 2025 | finance.yahoo.com

TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease

June 25, 2025 | finance.yahoo.com

TNF Pharmaceuticals Amends Bylaws to Alter Voting Rules

May 9, 2025 | tipranks.com

TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists

May 8, 2025 | businesswire.com

TNF Pharmaceuticals uses AI to refine patient selection for trials

April 24, 2025 | uk.investing.com

TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development

April 22, 2025 | finance.yahoo.com

TNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays Bearish

April 22, 2025 | msn.com

TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025

April 17, 2025 | finance.yahoo.com

TNF Pharmaceuticals, Inc. Common Stock (TNFA) Short Interest

April 3, 2025 | nasdaq.com

TNF Pharmaceuticals faces Nasdaq delisting over price

March 23, 2025 | investing.com

TNF Pharmaceuticals, Inc. Common Stock

March 20, 2025 | fxempire.comF

TNF Pharmaceuticals shares R&D progress on Isomyosamine

March 12, 2025 | uk.investing.com

TNF Pharmaceuticals initiates isomyosamine trial

February 25, 2025 | markets.businessinsider.com

TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor

February 25, 2025 | businesswire.com

TNFA stock touches 52-week low at $0.48 amid market challenges

February 14, 2025 | msn.com

TNFA stock touches 52-week low at $1.02 amid market challenges

January 30, 2025 | msn.com

How Does TNF Pharmaceuticals Inc (TNFA) Stack Up Against Its Industry Peers?

January 30, 2025 | bovnews.comB

TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

January 29, 2025 | tmcnet.com

TNF Pharmaceuticals to study TNF-alpha in patients taking GLP-1s

January 29, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNFA, CLRB, BMRA, and TAOX Company Descriptions

Biomerica NASDAQ:BMRA

$3.69 +0.66 (+21.68%)

As of 02:52 PM Eastern

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Cellectar Biosciences NASDAQ:CLRB

$4.39 -0.03 (-0.57%)

As of 02:47 PM Eastern

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Synaptogenix NASDAQ:TAOX

$8.94 -0.62 (-6.49%)

As of 02:24 PM Eastern

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

TNF Pharmaceuticals NASDAQ:TNFA

$0.10 0.00 (-3.81%)

As of 02:52 PM Eastern

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time